Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ALinC 17: Protocol for Patients With Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study

NCT00005603 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00005603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ALinC 17: Protocol for Patients With Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2000
Completion date
Not reported
Enrollment
276 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia